Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q2 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $8.3 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.

Earnings